Hypothesis

The cyclic GMP‑AMP synthase–STING (cGAS‑STING) DNA‑sensing pathway functions as an upstream coordinator that links primary aging insults—genomic instability, epigenetic drift, and mitochondrial dysfunction—to downstream antagonistic responses and integrative failures, thereby driving the coordinated emergence of the hallmarks of aging.

Mechanistic Rationale

• cGAS detects cytosolic DNA arising from nuclear chromatin leakage (epigenetic drift/genomic instability) and mitochondrial DNA release (mitochondrial dysfunction) [2, 3].
• Activated cGAS synthesizes 2'3'-cGAMP, which binds STING on the endoplasmic reticulum, triggering TBK1‑IRF3 signaling and, crucially, activating the NF‑κB pathway [5].
• Chronic STING signaling sustains NF‑κB/NLRP3 inflammasome activity, promoting sterile inflammation (inflammaging) and reinforcing a feedback loop where NF‑κB primes NLRP3 while p62/SQSTM1‑mediated mitophagy attempts to limit mtDNA release [3].
• Persistent STING‑NF‑κB signaling drives senescence-associated secretory phenotype (SASP) secretion, exacerbates stem cell exhaustion via inflammatory niche alteration, and disrupts intercellular communication, aligning with integrative hallmarks [1, 6].
• This places cGAS‑STING at a nexus where primary damages converge, amplifying antagonistic responses and culminating in the phenotypic hallmarks traditionally treated as separate entities.

Testable Predictions

1. Genetic or pharmacological inhibition of cGAS or STING in aged mice will concurrently reduce markers of genomic instability (γH2AX foci), epigenetic drift (DNA methylation entropy), mitochondrial dysfunction (mtROS, membrane potential), senescence (p16^INK4a^, SASP cytokines), stem cell depletion (colon crypt, muscle satellite cells), and altered communication (circulating inflammasome ligands).
2. The protective effects of cGAS‑STING loss will be attenuated in backgrounds lacking NF‑κB or NLRP3, indicating dependence on this inflammatory axis.
3. Tissue‑specific activation of cGAS‑STING (e.g., via inducible cytosolic DNA transfection) will recapitulate a multispectral aging phenotype, demonstrating sufficiency.
4. Single‑cell multi‑omics of aged wild‑type versus cGAS‑STING‑deficient tissues will reveal coordinated shifts across damage, response, and integration layers rather than isolated changes.

Potential Experimental Approach

• Models: Use ERT2‑Cre; cGAS^fl/fl^ and STING^fl/fl^ mice crossed with ubiquitous or tissue‑specific promoters; treat with low‑dose C-176 (STING inhibitor) or RU.521 (cGAS inhibitor) in aged cohorts (20‑24 months).
• Readouts: Quantify DNA damage (comet assay, γH2AX), epigenetic clocks (bisulfite sequencing), mitochondrial health (Seahorse, mtDNA copy number), senescence (SA‑β‑gal, p16, SASP proteomics), stem cell assays (colony‑forming, flow cytometry), and communication (serum IL‑1β, IL‑6, CXCL10 via Luminex).
• Analysis: Apply multivariate statistical models to test whether inhibition produces a unified improvement across all hallmark domains compared to single‑target controls (e.g., NF‑κB inhibition alone).

Falsifiability

If cGAS‑STING inhibition fails to significantly improve at least three distinct hallmark categories simultaneously, or if improvements are wholly abolished only when targeting a downstream effector unrelated to NF‑κB/NLRP3 (e.g., mTOR), the hypothesis that cGAS‑STING acts as an upstream integrative controller would be falsified. This framework offers a concrete, experimentally accessible route to evaluate whether a single DNA‑sensing node can orchestrate the multifaceted decline associated with aging.